SCHEMBL41788

SCHEMBL41788

Nc1nc2nc[nH]c2c(=O)n1N

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PNP P00491 1/20 0.50
DPP4 P27487 1/20 0.47
PDPK1 O15530 1/20 0.46
GDA Q9Y2T3 1/20 0.46
ALDH1A1 P00352 1/20 0.44
MAP3K5 Q99683 1/20 0.44
CDK2 P24941 3/20 0.43
PI4KA P42356 2/20 0.39
PI4K2B Q8TCG2 2/20 0.39
PI4K2A Q9BTU6 2/20 0.39
PI4KB Q9UBF8 2/20 0.39
LMNA P02545 2/20 0.39
DRD3 P35462 1/20 0.39
XDH P47989 1/20 0.39
LRRK2 Q5S007 1/20 0.39
ATAD2 Q6PL18 1/20 0.39
HRH4 Q9H3N8 1/20 0.38
PIK3CD O00329 1/20 0.38
ALPL P05186 1/20 0.38
ADORA3 P0DMS8 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Phosphoric Acid SCHEMBL27758697 0.92 PNP (0.44) PNPDPP4PDPK1GDAALDH1A1
Phosphoric Acid SCHEMBL27758691 0.92 PNP (0.44) PNPDPP4PDPK1GDAALDH1A1
SCHEMBL20579 0.81 DPP4 (0.50) PNPDPP4PDPK1GDAALDH1A1
SCHEMBL8886040 0.81 PNP (0.49) PNPDPP4PDPK1GDAALDH1A1
SCHEMBL27975255 0.81 PNP (0.49) PNPDPP4PDPK1GDAALDH1A1
SCHEMBL1843777 0.81 PNP (0.49) PNPDPP4PDPK1GDAALDH1A1
SCHEMBL20867 0.81 ATAD2 (0.53) PNPDPP4PDPK1GDALMNA
SCHEMBL2051365 0.81 PNP (0.49) PNPDPP4PDPK1GDAALDH1A1
SCHEMBL2983851 0.81 PNP (0.49) PNPDPP4PDPK1GDAALDH1A1
SCHEMBL852108 0.81 PNP (0.49) PNPDPP4PDPK1GDAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 324 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101784556-B Thiocarbon-protecting groups for rna synthesis AGILENT TECHNOLOGIES INC 2014-07-09 CN claimed
CN-103476947-A Enhanced biodistribution of oligomers GROOVE BIOPHARMA CORP 2013-12-25 CN claimed
CN-103068834-A Phosphoramidites for reverse RNA synthesis CHEMGENES CORP 2013-04-24 CN claimed
CN-102766182-A Method for synthesizing dideoxynucleoside through glycosyl transfer reaction and application thereof JIANGYIN SULI CHEMICAL CO LTD 2012-11-07 CN claimed
CN-1189562-C Antitumor antisense sequences directed against R1 and R2 components of ribonucleotide reductase GENESENSE TECHNOLOGIES INC (CA) 2005-02-16 CN claimed
CN-1160402-A Purine and guanine compounds as inhibitors of PNP CHIROSCIENCE LTD (GB) 1997-09-24 CN claimed
EP-4698674-A1 METHODS TO TREAT GLIOMA IN SUBJECTS WITH DEFINED TUMOUR MICROENVIRONMENT University Health Network (CA) 2026-02-25 EP disclosed
US-20260049318-A1 INHIBITION OF PLANT PROTEASE AED3-1 FOR IMPROVED HETEROLOGOUS PROTEIN PRODUCTION UNIV GUELPH (CA) 2026-02-19 US disclosed
WO-2025217257-A1 ENGINEERED CIRCULARIZED PEGRNAS AND USES THEREOF TRUSTEES OF BOSTON UNIVERSITY (US) 2025-10-16 WO disclosed
EP-4615994-A1 DNAZYME FOR EOSINOPHIL PEROXIDASE AND USES THEREOF McMaster University (CA) 2025-09-17 EP disclosed
WO-2025085704-A1 BRAIN-CELL SPECIFIC PARTIAL CELLULAR REPROGRAMMING TREATMENT AND PREVENTION METHODS FOR ALZHEIMER'S DISEASE AND PROGERIA, COMPOSITIONS THEREFORE, AND USES THEREOF YOUTHBIO THERAPEUTICS INC. (US) 2025-04-24 WO disclosed
WO-2024250102-A1 FOOD PACKAGING SYSTEM FOR DETECTING PATHOGENIC BACTERIA TOYOTA TSUSHO CANADA, INC. (CA) 2024-12-12 WO disclosed
US-20240392343-A1 METHODS TO SCREEN YEAST TO IDENTIFY XENOBIOTICS THAT TARGET PESTS, PATHOGENS AND PARASITES ROY PETER J (CA) 2024-11-28 US disclosed
CN-1229084-A Unsaturated phosphate derivatives of purines and pyrimidines MERRELL DOW PHARMA (US) 1999-09-22 CN disclosed
CN-1212693-A Process for preparing purine derivatives HOFFMANN LA ROCHE (CH) 1999-03-31 CN disclosed
CN-1192154-A Combinatorial libraries of substrate-bound cyclic organic compounds CHIRON CORP (US) 1998-09-02 CN disclosed
CN-1120338-A Unsaturated phosphonate derivatives of purines and pyrimidines MERRELL DOW PHARMA (US) 1996-04-10 CN disclosed
US-5412088-A 6-O-substituted guanosine derivatives RUTGERS, THE STATE UNIVERSITY (US) 1995-05-02 US disclosed
CN-1036578-A NOVEL FLUOROPHOSPHONATE NUCLEOTIDE DERIVATIVES MERRELL DOW PHARMA (US) 1989-10-25 CN disclosed
EP-0310365-A1 Engine seal compatible dispersant for lubricating oils AMOCO CORPORATION (US) 1989-04-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260049318-A1 INHIBITION OF PLANT PROTEASE AED3-1 FOR IMPROVED HETEROLOGOUS PROTEIN PRODUCTION DPP3, IDE, NOTCH3 PNP 1073/4885DPP4 34/4885PDPK1 794/4885
US-20240392343-A1 METHODS TO SCREEN YEAST TO IDENTIFY XENOBIOTICS THAT TARGET PESTS, PATHOGENS AND PARASITES CYP4X1, CYP7A1, CYP1A1 PNP 460/4885DPP4 3502/4885PDPK1 3070/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.